CytoPharm, Inc.   Report issue

For profit Phase 2
Founded: Taipei Taiwan (2003)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2009
NCT00695019
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

interferon alpha-2b (Intron-A) (2 trials)

maltose (1 trial)

oseltamivir (tamiflu) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Influenza, Human (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3